CSI Market
Sign In | Register

Pharmacyte Biotech Inc (PMCB) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PMCB quarterly Cash Flow →
A period-by-period view of cash flow from Pharmacyte Biotech Inc to Apr 30 2022 helps clarify how Apr 30 2026's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Apr 30 2026)
12 Months 		(Apr 30 2025) (Apr 30 2024) (Apr 30 2023) (Apr 30 2022)
Operating Activities
Income-42.63
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation0.89
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Derivative Liabilities0.00
Debt Instrument Decrease Forgiveness-
Shares Issued For Interest Expense-
Shares Pledged As Collateral-
Gainloss On Conversion Of Debt-
Impairment Loss Recognized For Fixed Assets-
Gains Losses On Forgiveness Of Debt-
Stock Issued During Period Value Issued For Services-
Stock Issued During Period Value Share Based Compensation-
Loss On Conversion Of Preferred Stock-
Extinguishment Of Debt Gain Loss Net Of Tax-
Share Based Compensation Options-
Share Based Compensation Warrants-
Gain On Related Party Investment T N F-
Change In Fair Value Of Warrant Liability-10.45
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss-
Change In Fair Value Of Convertible Note Receivable-
Gain On Investment In Preferrred Stock-21.40
Noncash Interest Income-0.30
Noncash Warrant Liability0.47
Impairment Of Intangible Assets Excluding Goodwill-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Other Accounts Payable-0.13
Increase (Decrease) in Other Accrued Liabilities-1.55
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.25
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities38.01
Discontinued operations0.00
Net Cash flow from Operating Activities-5.15
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Notes Receivable-
Payments To Acquire Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net2.00
Discontinued operations0.00
Net Cash Flow from Investing Activities2.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.65
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock6.40
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.46
Issuance Of Shares For Settlement Of Debt-
Stock Subscriptions Receivable-
Use Of Funds For Payment Of Insurance Financing Loan-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents50.18
Redemption Of Preferred Stock-22.49
Payment Of Series C Convertible Preferred Stock Dividends-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.58
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.15
Total Cash Flow3.43
4 historic quarters locked

Sign in to unlock the full Pharmacyte Biotech Inc cash flow history.

Sign In Create Free Account

About Pharmacyte Biotech Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001683168-26-005836

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License